Theophylline low-dose inhalation - Pulmagen Therapeutics

Drug Profile

Theophylline low-dose inhalation - Pulmagen Therapeutics

Alternative Names: ADC 4022; Theophylline Solution for Inhalation - Pulmagen

Latest Information Update: 19 Aug 2015

Price : $50

At a glance

  • Originator Argenta Discovery
  • Developer Argenta; Pulmagen Therapeutics
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Xanthines
  • Mechanism of Action Histone deacetylase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 31 Mar 2014 Argenta has been acquired by Charles River Laboratories
  • 02 Feb 2010 Argenta Discovery has been acquired by Galapagos NV
  • 16 Sep 2009 Efficacy and pharmacodynamics data from a phase II trial in chronic obstructive pulmonary disease were presented at the 19th Annual Congress of the European Respiratory Society(ERS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top